Who owns Xilio Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of XLO from SEC Form 13F filings across 26 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 26 institutions disclosed 2.8M shares of Xilio Therapeutics, Inc. worth $26.4M — about 14.2% of shares outstanding; the largest disclosed holder is Bain Capital Life Sciences Investors, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
26
13F holders
$26.4M
value, 2026 filers
14.2%
of shares outstanding (2.8M sh)
11
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of XLO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 664,021 | $6.4M | 0.4% | 3.4% | 0.0% |
| 2 | ORBIMED ADVISORS LLCNEW | 592,300 | $5.7M | 0.1% | 3.1% | new |
| 3 | Frazier Life Sciences Management, L.P. | 422,505 | $4.0M | 0.1% | 2.2% | 0.0% |
| 4 | Stonepine Capital Management, LLC | 225,994 | $2.2M | 1.2% | 1.2% | +252.2% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 178,517 | $1.7M | 0.0% | 0.9% | +44.4% |
| 6 | Sio Capital Management, LLC | 152,464 | $1.5M | 0.2% | 0.8% | 0.0% |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 111,541 | $1.1M | 0.0% | 0.6% | new |
| 8 | Merck & Co., Inc. | 105,982 | $1.0M | 0.2% | 0.5% | 0.0% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 64,153 | $614,586 | 0.0% | 0.3% | +29.4% |
| 10 | MORGAN STANLEY | 56,954 | $545,619 | 0.0% | 0.3% | -0.9% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 39,055 | $374,174 | 0.0% | 0.2% | +5.0% |
| 12 | CITADEL ADVISORS LLCNEW | 25,950 | $248,601 | 0.0% | 0.1% | new |
| 13 | VANGUARD FIDUCIARY TRUST CO | 22,594 | $216,451 | 0.0% | 0.1% | -20.7% |
| 14 | BRIDGEWAY CAPITAL MANAGEMENT, LLCNEW | 17,544 | $168,072 | 0.0% | 0.1% | new |
| 15 | TWO SIGMA INVESTMENTS, LPNEW | 14,544 | $139,332 | 0.0% | 0.1% | new |
| 16 | Velan Capital Investment Management LP | 14,285 | $136,850 | 0.1% | 0.1% | 0.0% |
| 17 | GSA CAPITAL PARTNERS LLP | 13,590 | $130,000 | 0.0% | 0.1% | -19.8% |
| 18 | STATE STREET CORP | 13,311 | $127,519 | 0.0% | 0.1% | 0.0% |
| 19 | PRELUDE CAPITAL MANAGEMENT, LLCNEW | 11,600 | $111,128 | 0.0% | 0.1% | new |
| 20 | BlackRock, Inc.NEW | 8,757 | $83,892 | 0.0% | 0% | new |
| 21 | Steward Partners Investment Advisory, LLCNEW | 714 | $6,840 | 0.0% | 0% | new |
| 22 | SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/NEW | 321 | $3,075 | 0.0% | 0% | new |
| 23 | BARCLAYS PLCNEW | 115 | $1,102 | 0.0% | 0% | new |
| 24 | Key Financial Inc | 59 | $565 | 0.0% | 0% | 0.0% |
| 25 | JONES FINANCIAL COMPANIES LLLPNEW | 29 | $262 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.